Evolution of Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials: A Clinical Trial Databank Analysis
United European Gastroenterology Journal · 2025
DOI: 10.1002/ueg2.12731 ↗Kurz gefasst
Fachartikel in der Zeitschrift United European Gastroenterology Journal, 2025. Verfasst von An Outtier und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Patient Selection, Randomized Controlled Trials as Topic, Colitis, Ulcerative, Crohn Disease. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Eligibility criteria in clinical trials have been criticised for being overly restrictive without clinical justification.
Objective
We aimed to investigate the types, evolution, and current status of eligibility criteria in clinical trials for inflammatory bowel diseases (IBD).
Methods
We performed a clinical trial databank search on clinicaltrials.gov , and included all Phase 3 placebo‐controlled randomised‐controlled trials (RCTs) investigating biologics or small molecules as induction therapy for moderate‐to‐severe Crohn's disease (CD) and ulcerative colitis (UC). Eligibility criteria were analysed both quantitatively and qualitatively.
Results
Fifty‐nine RCTs were identified between the year 2000 and 2022 (30 for CD and 29 for UC). The median (interquartile range) number of eligibility criteria was 44 (38–49), and did not significantly change over the studied time period ( p = 0.26). Qualitative analysis showed that common patient populations, such as older patients, therapy refractory patients, patients with comorbidities, prior malignancies, unclassified IBD type, ulcerative proctitis, stricturing and fistulizing CD, as well as patients with an ostomy, were often excluded. Heterogeneity in eligibility criteria across the different IBD clinical trials was found, such as for disease activity measurement, dosage of concomitant medication, wash‐out period of advanced therapies, and laboratory tests.
Conclusion
The median number of eligibility criteria for IBD RCTs did not significantly change over time. The eligibility criteria are however restrictive and complex, limiting the generalisability of efficacy and safety outcomes in daily practice when drugs are approved. Future research is needed to investigate the impact of broadening eligibility criteria to better encompass real‐world practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
- Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
- Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
ORCID-Profile: An Outtier, Bram Verstockt, Séverine Vermeire
Zitieren
APA
Outtier, A., Janssens, R., Barbier, L., Sabino, J., Verstockt, B., Vermeire, S., Huys, I., & Ferrante, M. (2025). Evolution of Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials: A Clinical Trial Databank Analysis. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12731
Vancouver
Outtier A, Janssens R, Barbier L, Sabino J, Verstockt B, Vermeire S, et al. Evolution of Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials: A Clinical Trial Databank Analysis. United European Gastroenterology Journal. 2025. doi:10.1002/ueg2.12731
BibTeX
@article{Outtier2025,
author = {Outtier, An and Janssens, Rosanne and Barbier, Liese and Sabino, João and Verstockt, Bram and Vermeire, Séverine and Huys, Isabelle and Ferrante, Marc},
title = {Evolution of Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials: A Clinical Trial Databank Analysis},
journal = {United European Gastroenterology Journal},
year = {2025},
doi = {10.1002/ueg2.12731}
}
EUVIMED